vs
Pacira BioSciences, Inc.（PCRX）とRanger Energy Services, Inc.（RNGR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Pacira BioSciences, Inc.の直近四半期売上が大きい（$177.4M vs $142.2M、Ranger Energy Services, Inc.の約1.2倍）。Ranger Energy Services, Inc.の純利益率が高く（2.3% vs 1.6%、差は0.6%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs -0.6%）。過去8四半期でRanger Energy Services, Inc.の売上複合成長率が高い（1.9% vs -0.2%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
レンジャー・エナジー・サービシズ社は北米屈指の陸上油田サービスプロバイダーであり、上流の石油・ガス事業者に対して坑井完成、修井、リグ運用、生産性向上ソリューションを提供し、主に米国本土のシェール・緻密資源開発地域で事業を展開しています。
PCRX vs RNGR — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $177.4M | $142.2M |
| 純利益 | $2.9M | $3.2M |
| 粗利率 | — | — |
| 営業利益率 | 3.9% | 2.3% |
| 純利益率 | 1.6% | 2.3% |
| 売上前年比 | 5.0% | -0.6% |
| 純利益前年比 | — | -44.8% |
| EPS（希薄化後） | $0.07 | $0.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $142.2M | ||
| Q3 25 | $179.5M | $128.9M | ||
| Q2 25 | $181.1M | $140.6M | ||
| Q1 25 | $168.9M | $135.2M | ||
| Q4 24 | $187.3M | $143.1M | ||
| Q3 24 | $168.6M | $153.0M | ||
| Q2 24 | $178.0M | $138.1M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $3.2M | ||
| Q3 25 | $5.4M | $1.2M | ||
| Q2 25 | $-4.8M | $7.3M | ||
| Q1 25 | $4.8M | $600.0K | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-143.5M | $8.7M | ||
| Q2 24 | $18.9M | $4.7M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 2.3% | ||
| Q3 25 | 3.5% | 2.0% | ||
| Q2 25 | 4.7% | 6.1% | ||
| Q1 25 | 1.2% | 0.7% | ||
| Q4 24 | 13.2% | 6.2% | ||
| Q3 24 | -82.8% | 8.4% | ||
| Q2 24 | 15.9% | 5.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.0% | 0.9% | ||
| Q2 25 | -2.7% | 5.2% | ||
| Q1 25 | 2.8% | 0.4% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | -85.1% | 5.7% | ||
| Q2 24 | 10.6% | 3.4% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.14 | ||
| Q3 25 | $0.12 | $0.05 | ||
| Q2 25 | $-0.11 | $0.32 | ||
| Q1 25 | $0.10 | $0.03 | ||
| Q4 24 | $0.38 | $0.24 | ||
| Q3 24 | $-3.11 | $0.39 | ||
| Q2 24 | $0.39 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $144.3M | $10.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $653.9M | $300.1M |
| 総資産 | $1.2B | $419.3M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $10.3M | ||
| Q3 25 | $246.3M | $45.2M | ||
| Q2 25 | $445.9M | $48.9M | ||
| Q1 25 | $493.6M | $40.3M | ||
| Q4 24 | $484.6M | $40.9M | ||
| Q3 24 | $453.8M | $14.8M | ||
| Q2 24 | $404.2M | $8.7M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $300.1M | ||
| Q3 25 | $727.2M | $270.0M | ||
| Q2 25 | $757.8M | $276.9M | ||
| Q1 25 | $798.5M | $272.6M | ||
| Q4 24 | $778.3M | $273.8M | ||
| Q3 24 | $749.6M | $267.6M | ||
| Q2 24 | $879.3M | $260.5M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $419.3M | ||
| Q3 25 | $1.3B | $372.8M | ||
| Q2 25 | $1.5B | $381.7M | ||
| Q1 25 | $1.6B | $376.5M | ||
| Q4 24 | $1.6B | $381.6M | ||
| Q3 24 | $1.5B | $373.9M | ||
| Q2 24 | $1.6B | $359.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $24.1M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $17.1M |
| FCFマージンFCF / 売上 | — | 12.0% |
| 設備投資強度設備投資 / 売上 | — | 4.9% |
| キャッシュ転換率営業CF / 純利益 | — | 7.53× |
| 直近12ヶ月FCF直近4四半期 | — | $42.9M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $24.1M | ||
| Q3 25 | $60.8M | $13.6M | ||
| Q2 25 | $12.0M | $20.7M | ||
| Q1 25 | $35.5M | $10.6M | ||
| Q4 24 | $33.1M | $32.7M | ||
| Q3 24 | $53.9M | $17.7M | ||
| Q2 24 | $53.2M | $22.1M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $17.1M | ||
| Q3 25 | $57.0M | $8.0M | ||
| Q2 25 | $9.3M | $14.4M | ||
| Q1 25 | $26.9M | $3.4M | ||
| Q4 24 | $31.0M | $27.3M | ||
| Q3 24 | $49.8M | $10.8M | ||
| Q2 24 | $51.6M | $6.8M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 12.0% | ||
| Q3 25 | 31.7% | 6.2% | ||
| Q2 25 | 5.1% | 10.2% | ||
| Q1 25 | 15.9% | 2.5% | ||
| Q4 24 | 16.6% | 19.1% | ||
| Q3 24 | 29.6% | 7.1% | ||
| Q2 24 | 29.0% | 4.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 2.2% | 4.3% | ||
| Q2 25 | 1.5% | 4.5% | ||
| Q1 25 | 5.1% | 5.3% | ||
| Q4 24 | 1.1% | 3.8% | ||
| Q3 24 | 2.4% | 4.5% | ||
| Q2 24 | 0.9% | 11.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.53× | ||
| Q3 25 | 11.20× | 11.33× | ||
| Q2 25 | — | 2.84× | ||
| Q1 25 | 7.37× | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | 2.82× | 4.70× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
